Matches in SemOpenAlex for { <https://semopenalex.org/work/W2240456670> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2240456670 abstract "e20671 Background: We previously showed on 31 cancer patients (pts) that early cardiac abnormalities occurred at epirubicin (EPI) doses of 200 mg/m 2 and persisted throughout subsequent EPI doses and even up to 18 months. Early contractility impairment, i.e. Strain rate (SR) reduction was detected by tissue doppler imaging (TDI) associated with high levels of inflammatory/oxidative stress markers. Renin-angiotensin system activation has been suggested to play an important role in the pathogenesis of Anthracycline-induced cardiotoxicity. Methods: A phase II placebo-controlled study was designed to investigate the possible role of telmisartan (an antagonist of angiotensine II type I receptor) in preventing both early preclinical and late myocardial damage induced by EPI. The correlation with changes of biochemical/inflammatory markers was also assessed. Planned sample size was 100 pts (50 pts per arm). Inclusion criteria: 18–70 y, histologically confirmed cancer, previously untreated and candidates for an EPI-based regimen; LVEF ≥55%; ECOG PS 0–2, no history of cardiac disease and previous mediastinal irradiation. Eligible pts were randomized to receive telmisartan 40 mg (1 tablet)/day or placebo starting 1 week before EPI until 6 months after the end of EPI administration. TDI as well as inflammatory/oxidative stress markers were assessed at baseline, 24 hours and 7 days at EPI doses of 100, 200, 300, and 400 mg/m 2 . Results: At December 2008 we enrolled 27 pts (M/F: 7/20, mean±SD age 58±14 years): 14 telmisartan and 13 placebo. 15 pts completed EPI treatment (8 telmisartan and 7 placebo). A significant reduction of SR peak was observed at 200mg/m2 of EPI in the placebo arm. Viceversa no significant TDI changes occurred in the treatment arm. Proinflammatory cytokines did not change in both arms whilst reactive oxygen species increased significantly in the placebo arm. Conclusions: The study is in progress. No significant financial relationships to disclose." @default.
- W2240456670 created "2016-06-24" @default.
- W2240456670 creator A5008109619 @default.
- W2240456670 creator A5060437987 @default.
- W2240456670 creator A5063604293 @default.
- W2240456670 creator A5073763585 @default.
- W2240456670 creator A5074038978 @default.
- W2240456670 creator A5074775264 @default.
- W2240456670 creator A5080262303 @default.
- W2240456670 creator A5080288457 @default.
- W2240456670 date "2009-05-20" @default.
- W2240456670 modified "2023-09-26" @default.
- W2240456670 title "Cardioprotective effect of telmisartan in cancer patients treated with epirubicin" @default.
- W2240456670 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e20671" @default.
- W2240456670 hasPublicationYear "2009" @default.
- W2240456670 type Work @default.
- W2240456670 sameAs 2240456670 @default.
- W2240456670 citedByCount "0" @default.
- W2240456670 crossrefType "journal-article" @default.
- W2240456670 hasAuthorship W2240456670A5008109619 @default.
- W2240456670 hasAuthorship W2240456670A5060437987 @default.
- W2240456670 hasAuthorship W2240456670A5063604293 @default.
- W2240456670 hasAuthorship W2240456670A5073763585 @default.
- W2240456670 hasAuthorship W2240456670A5074038978 @default.
- W2240456670 hasAuthorship W2240456670A5074775264 @default.
- W2240456670 hasAuthorship W2240456670A5080262303 @default.
- W2240456670 hasAuthorship W2240456670A5080288457 @default.
- W2240456670 hasConcept C121608353 @default.
- W2240456670 hasConcept C126322002 @default.
- W2240456670 hasConcept C143998085 @default.
- W2240456670 hasConcept C2779716603 @default.
- W2240456670 hasConcept C2780835546 @default.
- W2240456670 hasConcept C530470458 @default.
- W2240456670 hasConcept C71924100 @default.
- W2240456670 hasConcept C84393581 @default.
- W2240456670 hasConcept C98274493 @default.
- W2240456670 hasConceptScore W2240456670C121608353 @default.
- W2240456670 hasConceptScore W2240456670C126322002 @default.
- W2240456670 hasConceptScore W2240456670C143998085 @default.
- W2240456670 hasConceptScore W2240456670C2779716603 @default.
- W2240456670 hasConceptScore W2240456670C2780835546 @default.
- W2240456670 hasConceptScore W2240456670C530470458 @default.
- W2240456670 hasConceptScore W2240456670C71924100 @default.
- W2240456670 hasConceptScore W2240456670C84393581 @default.
- W2240456670 hasConceptScore W2240456670C98274493 @default.
- W2240456670 hasLocation W22404566701 @default.
- W2240456670 hasOpenAccess W2240456670 @default.
- W2240456670 hasPrimaryLocation W22404566701 @default.
- W2240456670 hasRelatedWork W1987679857 @default.
- W2240456670 hasRelatedWork W1991773279 @default.
- W2240456670 hasRelatedWork W2015261814 @default.
- W2240456670 hasRelatedWork W2086537918 @default.
- W2240456670 hasRelatedWork W2093462457 @default.
- W2240456670 hasRelatedWork W2138522874 @default.
- W2240456670 hasRelatedWork W2348073689 @default.
- W2240456670 hasRelatedWork W2409498385 @default.
- W2240456670 hasRelatedWork W2411982630 @default.
- W2240456670 hasRelatedWork W2420916444 @default.
- W2240456670 hasRelatedWork W2432945817 @default.
- W2240456670 hasRelatedWork W2551690908 @default.
- W2240456670 hasRelatedWork W2554921082 @default.
- W2240456670 hasRelatedWork W2594218231 @default.
- W2240456670 hasRelatedWork W2626720204 @default.
- W2240456670 hasRelatedWork W2745218523 @default.
- W2240456670 hasRelatedWork W2883721214 @default.
- W2240456670 hasRelatedWork W3111604815 @default.
- W2240456670 hasRelatedWork W3114293261 @default.
- W2240456670 hasRelatedWork W3201613600 @default.
- W2240456670 isParatext "false" @default.
- W2240456670 isRetracted "false" @default.
- W2240456670 magId "2240456670" @default.
- W2240456670 workType "article" @default.